0000899243-17-026845.txt : 20171117
0000899243-17-026845.hdr.sgml : 20171117
20171117174611
ACCESSION NUMBER: 0000899243-17-026845
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171113
FILED AS OF DATE: 20171117
DATE AS OF CHANGE: 20171117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: El-Hibri Fuad
CENTRAL INDEX KEY: 0001380185
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 171212159
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2017-11-13
2017-11-15
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380185
El-Hibri Fuad
400 PROFESSIONAL DRIVE, SUITE 400
GAITHERSBURG
MD
20879
1
1
1
0
Chairman
Common Stock
2017-11-13
4
M
0
20000
22.03
A
1550216
D
Common Stock
2017-11-13
4
S
0
20000
40.69
D
1530216
D
Common Stock
2017-11-14
4
M
0
20000
22.03
A
1550216
D
Common Stock
2017-11-14
4
S
0
20000
40.05
D
1530216
D
Common Stock
4344250
I
By Intervac, L.L.C.
Common Stock
1524155
I
By Biovac, L.L.C.
Employee Stock Options (Right to Buy)
22.03
2017-11-13
4
M
0
20000
0.00
D
2018-03-14
Common Stock
20000
67983
D
Employee Stock Options (Right to Buy)
22.03
2017-11-14
4
M
0
20000
0.00
D
2018-03-14
Common Stock
20000
47983
D
All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.
The selling price of $40.69 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $40.26 to $40.98, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The selling price of $40.05 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $39.81 to $40.55, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014.
/s/ Carl A. Valenstein, attorney-in-fact
2017-11-17